The biotech industry is at a crossroads, grappling with the challenges and expectations set by cell therapies. Oncology-focused treatments that once held great promise are now facing a reality check, prompting many companies to reevaluate their focus on autoimmune diseases. As expectations align
The quest for effective treatments in the fight against metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as non-alcoholic steatohepatitis (NASH), has reached an exciting new threshold. Boehringer Ingelheim has shared groundbreaking results from their Phase II clinical
In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a
The battle against cancer is one that has engaged the global medical community for decades, and with the emergence of Chimeric Antigen Receptor (CAR) T-cell therapy, we stand on the precipice of a significant revolution in the way cancer is treated. This immunotherapy transforms a patient's own
In a significant stride for medical science, PhoreMost Ltd., a biotechnological innovator, has forged a promising path in retinal therapy through its alliance with the pharmaceutical giant Boehringer Ingelheim. The joint venture, which kicked off in January 2020, has recently celebrated a crucial
Introduction Retro Biosciences, a pioneering biotech company, has embarked on an ambitious journey to extend human lifespan by a decade through innovative approaches to combat cellular aging. Its strategic partnership with Multiply Labs, a firm celebrated for advanced automation and robotic
